PAPooneh Akhavan

Pooneh Akhavan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Pooneh Akhavan has a total of 37 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Title: Impact of Coexisting Gout on Disease Activity in Rheumatoid Arthritis: Data from the Ontario Best Practices Research Initiative (OBRI)

    by Timothy Sh. Kwok, Mohammad Movahedi, Angela Cesta, Pooneh Akhavan, J Carter Thorne, Janet Pope, Arthur Lau, Reza Mirza, Elliott Hepworth, Andrew Chow, et al.

  • Defining Difficult‐to‐Treat Rheumatoid Arthritis in Routine Care: Comparative Performance of Published Criteria and Description of Early and Late Difficult‐to‐Treat Rheumatoid Arthritis Phenotypes

    by Rahaf Zyad Attar, Mohammad Movahedi, Angela Cesta Msc, Msc Pooneh Akhavan Md, Carter Thorne, Msc Janet Pope Md, Msc Timothy Kwok Md, Msc Arthur Lau Md, Msc Reza Mirza Md, Msc Elliott Hepworth Md, et al.

    Objective: Despite advances in treat‐to‐target strategies, a subset of patients with rheumatoid arthritis (RA) remains refractory to multiple therapies and is classified as having difficult‐to‐treat RA (D2T‐RA). Although EULAR has proposed classification criteria for D2T‐RA, these patients remain variably identified in real‐world practice because of heterogeneous applications. We aimed to compare the preformance of published applications of the EULAR D2T‐RA criteria in a real‐world RA cohort and to determine weather the timing of D2T‐RA development could distinguish early from late D2T‐RA phenotypes. Methods: Using data from the Ontario Best Practices Research Initiative, a longitudinal real‐world RA registry, we evaluated four literature‐derived adaptations of the EULAR D2T‐RA definition among patients initiating their first advanced therapy. These definitions differed in disease activity requirements, follow‐up duration, and treatment count thresholds. We assessed prevalence, agreement between definitions, and explored different temporal anchors for classifying early versus late D2T‐RA. Results: Among 1,121 patients with RA (mean age 56.0 years; 80.7% female; mean disease duration of 8.4 years), 202 (18%) fulfilled at least one of four D2T‐RA definitions. Prevalence varied substantially across definitions, ranging from 5.5% (definition 4) to 11.7% (definition 2). Definitions 1 and 2, which incorporated multiple disease activity measures, identified the largest proportion of patients, whereas definition 4, which is defined solely by initiation of a third advanced therapy, was most restrictive. Overlap between definitions was modest, with only 44% of patients meeting all definitions 1 through 3, whereas definition 4 identified a distinct group with no overlap with the other definitions, suggesting that these classification approaches capture different patient subsets and are not interchangeable. In temporal analyses, anchoring the D2T‐RA onset to the initiation of the first advanced therapy, a two‐year threshold—selected for its clinical relevance and balanced group sizes—classified approximately 40% of patients as early and approximately 60% as late D2T‐RA. Conclusion: The applications of D2T‐RA criteria are not interchangeable and vary widely in patient capture. A two‐year threshold anchored to the first initiation of advanced therapy offered a clinically balanced early–late D2T‐RA framework. Harmonized, multidimensional definitions incorporating disease activity and temporal stratification are needed to improve phenotyping, prognostication, and cross‐study comparability.

  • Open Access

    Impact of Rheumatoid Arthritis Treatment Classes on Cardiovascular, Thromboembolic, Cancer Outcomes, and All-Cause Mortality: A Population-Based Cohort Study

    by Mohammad Movahedi, Angela Cesta, Sibel Zehra Aydin, Pooneh Akhavan, Tetyana Kendzerska, Claire Bombardier, Bindee Kuriya

    Background: Rheumatoid arthritis (RA) is linked to increased risks of major adverse cardiovascular events (MACE), venous thromboembolism (VTE), malignancy, and mortality. However, differences in these risks by treatment class—particularly among older adults with cardiovascular (CVD) risk factors—remain unclear. Methods: We conducted a population-based cohort study using Ontario administrative data. Patients aged ≥67 years with incident RA (2008–2013) were followed through 2023. Outcomes included healthcare utilization for MACE and VTE, all-cause mortality, and cancer-related encounters. Time-varying treatment groups were: no csDMARD/advanced therapy (AT), glucocorticoids (GC) only, csDMARDs (reference), and biologic/targeted synthetic DMARDs (b/tsDMARDs). Weighted Fine–Gray models within a marginal structural framework were used, stratified by baseline CVD risk. Results: Among 10,058 patients, 80% had high CVD risk. Compared with csDMARDs, untreated patients (SHR 15.0; 95% CI 13.8–16.2) and GC users (SHR 1.29; 95% CI 1.13–1.47) had higher MACE risk, while AT use was associated with lower risk (SHR 0.53; 95% CI 0.37–0.77). Similar patterns were observed in low-risk patients. AT use was not associated with VTE. Untreated and GC users had increased mortality, whereas AT use reduced mortality. Increased cancer-related utilization was observed only in untreated patients. Conclusion: Treatment type strongly influences major outcomes in older adults with RA, underscoring the importance of integrating CVD and thrombotic risk into therapeutic decisions.

  • Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #3

    by Roko P. A. Nikolic, Arnav Agarwal, Jordi Pardo Pardo, Pooneh Akhavan, Hugues Allard-Chamard, Claire E.H. Barber, Cheryl Barnabe, Shahin Jamal, Bindee Kuriya, Alexandra Legge, et al.

  • Open Access

    Canadian Rheumatology Association Living Guidelines for Rheumatoid Arthritis: Update #2

    by Roko P.A. Nikolic, Jordi Pardo Pardo, Janet E. Pope, Claire E.H. Barber, Cheryl Barnabe, Orit Schieir, Shahin Jamal, Alexandra Legge, Bindee Kuriya, Pooneh Akhavan, et al.

    We have updated the Canadian Rheumatology Association (CRA) guidelines for rheumatoid arthritis (RA) with 3 recommendations for the use of glucocorticoids (GCs). The recommendations address the use of short-term GCs for RA flares or as bridging therapy when disease-modifying antirheumatic drugs (DMARDs) are initiated or changed, and the use of longterm GCs as adjuncts to DMARDs.